Comparative test of the effectiveness of clindamycin phosphate and lincomycin hydrochloride on acute pneumonia (I)

Abstract

The therapeutic effectiveness of CLDM-P was investigated in a well-controlled study using LCM as control in the treatment of acute pneumonia due to gram-positive cocci, mycoplasma and anaerobic organisms. CLDM-P and LCM were given intramuscularly in a dose of 600 mg twice dailyfor a period of two weeks, as a rule. Out of 30 patients treated with CLDM-P and 27 with LCM, 46 were accepted for evaluation as cases of acute pneumonia. Eighteen (18) of them received CLDM-P and 19 LCM for bacterial pneumonia and another 5 CLDM-P and 4 LCM for mycoplasmal pneumonia. CLDM-P and LCM proved effective in 88.9% and 89.5% of patients with bacterial pneumonia respectively. They were also effective in 100% of patients with mycoplasmal pneumonia respectively. No significant difference was noted between two treatment groups in the incidence of side effects nor in the degree of utility as rated by doctors incharge. These findings indicate that CLDM-P is as useful a drug as LCM in treating acute pneumonia.